Phase 1 × Terminated × Myelodysplastic Syndromes × Clear all A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
Phase 1 Terminated
3 enrolled
Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Phase 1 Terminated
58 enrolled
LAUREL
Phase 1 Terminated
2 enrolled
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Phase 1 Terminated
106 enrolled 28 charts
Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 Terminated
18 enrolled 19 charts
Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease
Phase 1 Terminated
4 enrolled
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
Phase 1 Terminated
20 enrolled
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Phase 1 Terminated
28 enrolled 19 charts
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
Phase 1 Terminated
25 enrolled
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Phase 1 Terminated
56 enrolled 24 charts
Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
Phase 1 Terminated
56 enrolled
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
Phase 1 Terminated
7 enrolled 16 charts
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Phase 1 Terminated
101 enrolled 54 charts
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
Phase 1 Terminated
16 enrolled 13 charts
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS
Phase 1 Terminated
45 enrolled
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
Phase 1 Terminated
7 enrolled
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 1 Terminated
68 enrolled
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
Phase 1 Terminated
95 enrolled 47 charts
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia
Phase 1 Terminated
37 enrolled 14 charts
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Phase 1 Terminated
249 enrolled 43 charts
Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase 1 Terminated
39 enrolled
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
Phase 1 Terminated
40 enrolled
Encore-MDS
Phase 1 Terminated
127 enrolled
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Phase 1 Terminated
21 enrolled
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Phase 1 Terminated
24 enrolled 21 charts
SS1
Phase 1 Terminated
14 enrolled
IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT
Phase 1 Terminated
6 enrolled
A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies
Phase 1 Terminated
40 enrolled
Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Phase 1 Terminated
74 enrolled 30 charts
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
Phase 1 Terminated
2 enrolled
Phase I Study of Milatuzumab for Graft Versus Host Disease
Phase 1 Terminated
12 enrolled
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Phase 1 Terminated
5 enrolled
USBTXA127CBT
Phase 1 Terminated
20 enrolled
Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Phase 1 Terminated
5 enrolled
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant
Phase 1 Terminated
13 enrolled
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
Phase 1 Terminated
1 enrolled
UF-BMT-MRD-101
Phase 1 Terminated
11 enrolled 3 charts
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
Phase 1 Terminated
2 enrolled
Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Phase 1 Terminated
13 enrolled
Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML
Phase 1 Terminated
16 enrolled 9 charts
A Study of PLX51107 in Advanced Malignancies
Phase 1 Terminated
50 enrolled
Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 Terminated
19 enrolled
A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)
Phase 1 Terminated
28 enrolled
Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies
Phase 1 Terminated
14 enrolled
POE07-01
Phase 1 Terminated
35 enrolled
AHN-12 Biodistribution in Advanced Leukemia
Phase 1 Terminated
8 enrolled
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
Phase 1 Terminated
3 enrolled
Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia
Phase 1 Terminated
4 enrolled
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase 1 Terminated
3 enrolled